SCD and Parkinson disease: Two PD patient-derived iPSC lines harboring either the A53T mutation or gene triplication (S3) in the SNCA gene were used to evaluate the effect of SCD inhibition by YTX-7739 on multiple disease-relevant phenotypes (Fig. 2A).